In 1967, pioneering work by Ruth Nussenzweig demonstrated for the first time that irradiated
sporozoites of the rodent malaria parasite Plasmodium berghei protected mice against a …

The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based
particle vaccine, RTS, S, which targets the pre-erythrocytic stage of Plasmodium falciparum …

Antibodies against the NANP repeat of circumsporozoite protein (CSP), the major surface
antigen of Plasmodium falciparum (Pf) sporozoites, can protect from malaria in animal …

Malaria as vector-borne disease remains important health concern with over 200 million
cases globally. Novel antimalarial medicines and more effective vaccines must be …

Plasmodium gene functions in mosquito and liver stages remain poorly characterized due to
limitations in the throughput of phenotyping at these stages. To fill this gap, we followed …

Glutaminyl cyclase (QC) modifies N-terminal glutamine or glutamic acid residues of target
proteins into cyclic pyroglutamic acid (pGlu). Here, we report the biochemical and functional …

Despite recent advances in treatment and vector control, malaria is still a leading cause of
death, emphasizing the need for an effective vaccine. The malaria life cycle can be …

Adjuvanted protein vaccines offer high efficacy, yet most potent adjuvants remain
proprietary. Several adjuvant compounds are being developed by the Vaccine Formulation …

Mouse models are useful for the early down-selection of malaria vaccine candidates. The
Walter Reed Army Institute of Research has optimized a transgenic Plasmodium berghei …

Recent studies have shown that immune responses against the cell-traversal protein for
Plasmodium ookinetes and sporozoites (CelTOS) can inhibit parasite infection. While these …